IPP Bureau
Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
By IPP Bureau - February 07, 2026
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
By IPP Bureau - February 07, 2026
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
By IPP Bureau - February 07, 2026
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
By IPP Bureau - February 07, 2026
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
By IPP Bureau - February 07, 2026
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls
By IPP Bureau - February 06, 2026
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
By IPP Bureau - February 06, 2026
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure
By IPP Bureau - February 05, 2026
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Zydus receives FDA’s tentative approval for Dapagliflozin Tablets
By IPP Bureau - February 05, 2026
Lupin launches Topiramate ER capsules in US
By IPP Bureau - February 05, 2026
Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
By IPP Bureau - February 05, 2026
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Novo Nordisk weathers pricing pressure, bets big on oral Wegovy
By IPP Bureau - February 05, 2026
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
By IPP Bureau - February 05, 2026
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
By IPP Bureau - February 05, 2026
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
By IPP Bureau - February 05, 2026
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
